Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction-Reference-Cited by-同舟云学术

Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction

Published:2008-11 Issue:19 Volume:52 Page:1540-1545
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Udelson James E.,Orlandi Cesare,Ouyang John,Krasa Holly,Zimmer Christopher A.,Frivold Geir,Haught W. Herbert,Meymandi Sheiba,Macarie Cezar,Raef Dimitar,Wedge Patricia,Konstam Marvin A.,Gheorghiade Mihai

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference15 articles.

1. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure;Szatalowicz;N Engl J Med,1981

2. Increased plasma arginine vasopressin levels in patients with congestive heart failure;Goldsmith;J Am Coll Cardiol,1983

3. Plasma ADH level in patients with chronic congestive heart failure;Yamane;Jpn Circ J,1968

4. Vasopressin antagonism in heart failure;Goldsmith;J Am Coll Cardiol,2005

5. Vasopressin receptor blockade in patients with congestive heart failure: results from a randomized, double blind study;Gheorghiade;Circulation,2003

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Copeptin associates with major adverse cardiovascular events in patients on maintenance hemodialysis;Clinica Chimica Acta;2025-01

2. Neurohumoral Activation in Heart Failure;International Journal of Molecular Sciences;2023-10-23

3. Tolvaptan for water retention in heart failure: a systematic review;Systematic Reviews;2023-07-29

4. Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period;Kidney Research and Clinical Practice;2023-03-31

5. Pathophysiology of heart failure and an overview of therapies;Cardiovascular Pathology;2022